At BIIR, researchers have been working for over 10 years on dendritic cell vaccines that target melanoma.
First, the dendritic cell vaccines are extremely safe.
Two ongoing clinical trials at BIIR are designed to test whether clinical response rates to dendritic cell vaccines in patients with stage IV melanoma can be increased by pretreating patients with low-dose cyclophosphamide to eliminate or control naturally occurring suppressor T cells.
Although the technology developed at BIIR to construct dendritic cell vaccines has focused on melanoma, it is readily adaptable to other cancer types.
LEAPS-peptide vaccines and LEAPS-based dendritic cell vaccines
have the potential to provide safe and effective protection and treatment for infectious, oncogenic and autoimmune diseases.
DCOne-based dendritic cell vaccines
, in some indications loaded with cancer antigens for targeted treatment, are used as standardized, therapeutic products.
Profiling the T-cell repertoire is also being widely incorporated into clinical studies to assess the efficacy of treatments specifically designed to induce an immune response to cancer, including checkpoint inhibitors such as anti-CTLA, dendritic cell vaccines
, and vaccination with patient-specific tumor-derived neoantigens.
These new results demonstrate the potential of an ex vivo RNAi approach to strongly improve the immunogenicity of dendritic cell vaccines toward tumor antigens.
While much progress has been made in the development of dendritic cell vaccines in cancer, there is a clear need to improve this strategy for increased clinical benefit.
Various statements in this release concerning Alnylam's future expectations, plans and prospects, including without limitation, statements regarding Alnylam's views with respect to the potential for RNAi therapeutics, including applications of RNAi to enhance dendritic cell vaccines for cancer and chronic viral infections, and Alnylam's expectations regarding its "Alnylam 5x15" product strategy, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.
Dendritic cell vaccines
for gliomas, Luptrawan, Liu, S.
Published preclinical studies have shown that incorporating an ARGENT-inducible protein under dimerizer control into dendritic cell vaccines
greatly improves the potency and longevity of the anti-tumor response observed (see, Hanks, B.